- Kadmon is one of the highest shorted tickers on NASDAQ.
- Even a major drug approval didn't change that attitude.
- Sanofi is paying more than twice the current market cap to acquire KDMN.
- Run, baby, run.
For further details see:
Kadmon, The Big ShortFor further details see:
Kadmon, The Big ShortMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
2024-05-18 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
Wednesday, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine received World Health Organization’s (WHO) preq...